DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20162420

Flibanserin: a serendipitous story

Melvin George, Damal Kandadai Sriram, Venkatesan Surendran

Abstract


Female sexual disorders are increasingly being recognized in the population and hypoactive sexual desire disorder (HSDD) is one of the commonest sexual disorders among females. The prevalence of the disease varies between 10-20% in the Caucasian population. Testosterone is the only treatment that is approved by the European Medical Agency. Flibanserin is a drug that has been approved by the US FDA for HSDD among pre-menopausal women in 2015. Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist that rebalances the neural circuitry involved in processing sexual desire by reducing serotonin activity and enhancing dopamine and epinephrine activity. The efficacy of the drug was confirmed in three pivotal randomized placebo control trials in premenopausal women who consumed the drug for 24 weeks. There was a significant improvement in the number of sexually satisfying events. The most common safety concerns for flibanserin as seen in clinical trials were somnolence, hypotension and syncope. The drug is prescribed at a dose of 100 mg once daily at bed time. The marginal efficacy of the drug coupled with other safety concerns, such as hypo-tensions have given room for much criticism over the drug’s approval by the FDA. Nevertheless, on a positive note the serendipitous discovery of flibanserin and its repurposing for HSDD is a compelling narrative in its drug development history. It remains to be seen if the long term safety of the molecule and the efficacy of the molecule in non-trial settings could make it an attractive pharmaco-therapeutic option for HSDD.


Keywords


Flibanserin, HSDD, FSFI, SSE, eDairy score

Full Text:

PDF

References


Warnock JJK. Female hypoactive sexual desire disorder: epidemiology, diagnosis and treatment. CNS Drugs. 2002;16(11):745-53.

Clayton AH, Maserejian NN, Connor MK, Huang L, Heiman JR, Rosen RC. Depression in premenopausal women with HSDD: baseline findings from the HSDD registry for women. Psychosom Med. 2012;74(3):305-11.

Johannes CB, Clayton AH, Odom DM, Rosen RC, Russo PA, Shifren JL, et al. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry. 2009;70(12):1698-706.

Nappi RE, Martini E, Terreno E, Albani F, Santamaria V, Tonani S, et al. Management of hypoactive sexual desire disorder in women: current and emerging therapies. Int J Womens Health. 2010;2:167-75.

Palacios S. Hypoactive sexual desire disorder and current pharmacotherapeutic options in women. Womens Health Lond Engl. 2011;7(1):95-107.

Joffe HV, Chang C, Sewell C, Easley O, Nguyen C, Dunn S, et al. FDA approval of flibanserin-treating sypoactive sexual desire disorder. N Engl J Med. 2016;374(2):101-4.

Stahl SM. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015;20(1):1-6.

Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9(3):793-804.

Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med. 2012;9(4):1074-85.

Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807-15.

Risk evaluation and mitigation strategy (REMS). Available at http://www.accessdata.fda.gov/drugsatfda_docs/rems/Addyi_2016-04-08_REMS_full.pdf. Accessed on 21 April 2016.

Highlights of prescribing information. 2015. Available at www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf. Accessed on 21 April 2016.

Kennedy S. Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. J Sex Med. 2010;7(10):3449-59.

Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause N Y N. 2014;21(6):633-40.

Flibanserin (Addyi) for hypoactive sexual desire disorder. Med Lett Drugs Ther. 201528;57(1478):133-5.